Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) and Lipella Pharmaceuticals (NASDAQ:LIPO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Sagimet Biosciences and Lipella Pharmaceuticals, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Sagimet Biosciences | 0 | 1 | 4 | 0 | 2.80 |
Lipella Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
Sagimet Biosciences currently has a consensus price target of $24.00, suggesting a potential upside of 692.08%. Lipella Pharmaceuticals has a consensus price target of $2.00, suggesting a potential upside of 369.37%. Given Sagimet Biosciences’ higher probable upside, research analysts clearly believe Sagimet Biosciences is more favorable than Lipella Pharmaceuticals.
Earnings and Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Sagimet Biosciences | $2.00 million | 46.04 | -$27.88 million | N/A | N/A |
Lipella Pharmaceuticals | $449,617.00 | 7.21 | -$4.62 million | N/A | N/A |
Lipella Pharmaceuticals has lower revenue, but higher earnings than Sagimet Biosciences.
Profitability
This table compares Sagimet Biosciences and Lipella Pharmaceuticals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Sagimet Biosciences | N/A | -23.16% | -22.26% |
Lipella Pharmaceuticals | -991.79% | -171.66% | -145.43% |
Institutional and Insider Ownership
87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 17.6% of Sagimet Biosciences shares are owned by insiders. Comparatively, 39.6% of Lipella Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Sagimet Biosciences beats Lipella Pharmaceuticals on 8 of the 11 factors compared between the two stocks.
About Sagimet Biosciences
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
About Lipella Pharmaceuticals
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Receive News & Ratings for Sagimet Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagimet Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.